相关实验视频

Updated: Jun 17, 2026

Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice

Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice

Published on: March 1, 2017

血清神经丝光链测量是否会影响多发性硬化症治疗决策?

Gustavo Saposnik¹, Enric Monreal², Nicolas Medrano³

¹Division of Neurology, Department of Medicine, St. Michael´s Hospital, University of Toronto, Toronto, Canada; Clinical Outcomes and Decision Neuroscience Unit, Li Ka Shing Institute, University of Toronto, Toronto, Canada.

Multiple sclerosis and related disorders

|August 31, 2024

概括

治疗惯性在多发性硬化症 (MS) 护理中很常见,神经科医生经常推迟治疗决策,即使血清神经丝光链 (sNfL) 水平升高. 专业化和创新采用等因素影响了这些决定.

科学领域:

神经学神经学
生物标志物研究生物标志物研究
临床决策 - 临床决策

背景情况:

血清神经纤维光链 (sNfL) 是预测多发性硬化症 (MS) 治疗结果和治疗反应的宝贵工具.
对sNfL测量的临床实施仍然有限.
本研究调查了sNfL测量如何影响神经病学家在MS管理中的治疗决策.

研究的目的:

评估血清神经丝光链 (sNfL) 测量对神经病学家在多发性硬化症 (MS) 治疗决策的影响.
识别导致MS管理中的治疗惯性 (TI) 的因素.
探索sNfL水平和治疗决策之间的关系.

主要方法:

一个横截面的,基于网络的研究,涉及神经科医生管理多发性硬化症患者.
介绍了多发性硬化症患者的模拟病例情景 (第一个脱髓化事件或复发性复发性硬化症).
治疗惯性 (TI) 被定义为尽管sNfL水平升高,但没有开始/加剧治疗;计算了TI分数 (0-9).

主要成果:

116名神经科医生参与了这项研究,92.2%的患者至少在两个情景下表现出TI.
较高的TI分数与缺乏对MS护理的全力投入 (p=0.014),不喜欢风险的偏好 (p=0.008) 和低采用创新 (p=0.009) 有关.
平均TI得分为3.65 (SD1.01). 平均TI得分为3.65 (SD1.01).

结论:

在神经病学家之间,治疗惯性是普遍存在的,当根据高SNfL水平决定MS治疗时.
了解与TI相关的因素对于优化MS治疗决策至关重要.
这突显了生物标志物的可用性和MS管理中的临床实践之间的差距.

关键词:

生物标志物生物标志物多发性硬化症是多发性硬化症.个性化医疗是个性化的医疗.血清神经纤维光链中的光链.治疗惯性是一种治疗惯性.

更多相关视频

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice

Quantitative Measurement of Intrathecally Synthesized Proteins in Mice

Published on: November 29, 2019

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis

Published on: February 23, 2024

相关概念视频

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...